Tesamorelin Storage and Stability: What Studies Report

Two of the most common questions typed into search engines about this compound are whether tesamorelin needs refrigeration, and whether it needs refrigeration after reconstitution. This page summarises what the published literature actually contains on those points — which is less than many readers expect — and then sets out the general peptide-stability principles that stability scientists apply to lyophilized peptides of this class when compound-specific data are absent. This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about a medication, its storage, or its use.

What kind of molecule tesamorelin is

Reviews published as the compound moved through development described tesamorelin as a synthetic analogue of human growth hormone-releasing factor (GRF, also written GHRH), developed for HIV-associated lipodystrophy (PMID 17086939, PMID 19243281). A later drug review summarised its use in the management of HIV-associated lipodystrophy and reported that it was administered as a once-daily subcutaneous injection of 2 mg (PMID 21668043). A pharmacotherapy review reached the same description of the 2 mg daily subcutaneous regimen used in the registration programme (PMID 22298602).

That matters for a storage discussion for one reason: a daily-injection peptide supplied as a freeze-dried (lyophilized) powder has two distinct stability states — the dry solid, and the aqueous solution created when diluent is added. Stability scientists treat these as separate problems with separate shelf lives, and regulatory labeling for approved peptide products almost always states different conditions for each.

Does the published literature contain tesamorelin stability studies?

Not in the peer-reviewed clinical record indexed for this compound. The tesamorelin papers that exist are efficacy, safety, pharmacokinetic and mechanistic studies. A population pharmacokinetic and pharmacodynamic analysis characterised the compound's behaviour in HIV-infected patients and healthy subjects, meaning the exposure profile after injection has been modelled (PMID 25895899). Trials reported reductions in visceral adipose tissue and associated changes in liver enzymes (PMID 28832410), changes in inflammatory markers linked to visceral fat reduction (PMID 21516030), and changes in fat quality independent of fat quantity (PMID 33756511). None of those papers is a stability study, and none of them reports assay data on vials held at different temperatures.

This is normal. Formal stability testing for an approved drug is performed by the manufacturer under regulatory guidelines and reported in the product dossier and labeling, not usually as a standalone journal article. So the honest answer to "what do studies report about tesamorelin storage?" is: the storage conditions that exist in the public domain come from approved-product labeling and from general peptide chemistry, while the journal literature covers what the drug did in people rather than how the vial behaved on a shelf.

Lyophilized powder versus reconstituted solution

Freeze-drying removes most of the water that drives chemical degradation. In the dry state, the reaction rates for hydrolysis and deamidation fall dramatically, which is why lyophilized peptides are typically assigned shelf lives measured in months to years while their reconstituted solutions are assigned shelf lives measured in hours to days.

Approved tesamorelin products are supplied as a sterile lyophilized powder with a diluent, and the labeling distinguishes the storage condition for the unmixed vial from the handling of the solution after mixing, with the reconstituted solution intended to be used promptly rather than stored long-term. Labeling has differed between formulations of the product over time, which is precisely why generalising from one package insert to another — or from an approved product to research-grade material — is unreliable. Readers looking for the authoritative statement for a specific product are directed to that product's own current labeling and to a licensed physician or pharmacist.

Why the dry state is more forgiving

• Water is a reactant. Hydrolysis of amide bonds and deamidation of asparagine and glutamine residues both require water; removing it slows both.
• Molecular mobility is restricted. In a glassy lyophilized cake, peptide chains cannot easily unfold or collide, which limits aggregation.
• Excipients contribute. Bulking agents and stabilisers used in lyophilized peptide formulations form the cake structure and help preserve conformation during drying and storage.
• Residual moisture still matters. Stability scientists monitor residual water content in lyophilized products because higher residual moisture has repeatedly been associated with faster degradation in dry peptide and protein formulations.

Temperature: what general peptide stability science reports

Degradation of peptides in solution follows temperature-dependent kinetics, so the same vial held warmer degrades faster. That principle underlies the standard structure of pharmaceutical stability programmes, which run long-term, intermediate and accelerated conditions in parallel and use the accelerated data to flag the pathways that will eventually limit shelf life.

Because tesamorelin-specific numbers for these conditions are not in the peer-reviewed record, no shelf-life figure should be inferred from the table above. It describes how stability testing is organised, not how this molecule performed.

Freeze-thaw

Freeze-thaw cycling is tested separately from storage temperature because the stresses are different. During freezing, ice formation concentrates solutes in the remaining liquid, shifts local pH as buffer components crystallise at different rates, and creates large ice–water interfaces at which peptides can unfold or aggregate. Repeated cycles compound these effects. For that reason, stability protocols for peptide and protein products commonly specify a defined number of freeze-thaw cycles as a stress test, and many finished aqueous formulations carry explicit instructions against freezing. Lyophilized powder, by contrast, has little free water to freeze, which is part of why dry presentations are used for products that must be shipped and stored widely.

Light exposure

Photostability is a recognised category in international stability guidance, and peptides containing aromatic residues such as tryptophan, tyrosine and phenylalanine, or sulfur-containing residues such as methionine and cysteine, are the usual targets of light-driven oxidation. Photo-oxidation can generate modified residues and, in some cases, fragments or aggregates. This is why peptide vials are routinely supplied in cartons or amber containers and why photostability testing exposes samples to defined light doses to determine whether protective packaging is required. No published photostability dataset specific to tesamorelin appears in the clinical literature summarised here.

Container, surfaces and adsorption

At the low concentrations typical of peptide solutions, a measurable fraction of the peptide can adsorb onto container walls, stoppers, filters, syringes and tubing. Loss to surfaces is a recognised analytical problem in peptide bioanalysis and formulation work, and it is addressed with surfactant excipients, siliconised or low-binding containers, and validated recovery testing. Other container-related variables studied in stability programmes include the elastomeric closure (extractables and leachables, moisture ingress), glass delamination, and headspace oxygen, which interacts with oxidation-prone residues. Container-closure integrity testing is also what underpins any statement about how long a punctured multi-dose vial can be considered suitable, since microbiological risk — not only chemistry — governs in-use limits.

Diluent, pH and concentration

Once a lyophilized peptide is dissolved, the properties of the solution govern its fate. Three variables dominate in the published peptide-stability literature:

1. pH. Deamidation, hydrolysis and disulfide exchange each have characteristic pH dependencies, so the pH of the reconstituted solution — set by the formulation buffer and the diluent used — often determines which pathway limits stability.
2. Buffer and ionic composition. Buffer species can catalyse degradation, and buffer selection is therefore a formulation decision rather than an incidental detail.
3. Concentration. Aggregation is concentration-dependent, while adsorptive losses matter proportionally more at very low concentrations.

Bacteriostatic diluents, where used, address microbial growth rather than chemical degradation; preservatives do not extend chemical shelf life and can themselves interact with peptide formulations. Any specific diluent, pH or in-use window for an approved tesamorelin product is a labeling question for that product, not something the journal literature resolves.

What the clinical literature does establish about handling

Although the trials were not stability studies, they were conducted with product prepared and administered under protocol-controlled conditions, which is part of why their results are interpretable. Investigators reported effects on visceral fat, liver enzymes, inflammatory markers, fat quality and, in later work, neurocognitive endpoints in people with HIV and abdominal obesity (PMID 39813152). A trial in people with HIV taking integrase inhibitors evaluated efficacy and safety in that population (PMID 38905488), and a targeted proteomic and transcriptomic analysis examined response pathways in HIV-associated NAFLD (PMID 34006921). A published protocol for an exercise-adjunct trial illustrates how ongoing studies specify drug supply and administration procedures in advance (PMID 42419889). In each case the study documentation, not the published abstract, carries the handling detail.

Research-grade material versus approved product

Material sold for laboratory research is generally labeled research use only and is not manufactured, tested or released against the specifications that apply to an approved injectable drug. That distinction affects storage questions directly: an approved product's storage statement is supported by a formal stability dataset for that exact formulation, fill volume, closure and carton, whereas a research-grade vial may carry a supplier recommendation without a comparable public dataset behind it. Peptide identity, purity, counter-ion content, residual moisture and excipient composition can all differ, and each of those variables influences stability. Comparing the two as if they were interchangeable is the single most common error in online storage discussions.

Limits of the evidence

• No peer-reviewed stability study specific to tesamorelin appears in the literature summarised on this page; the storage principles described here are drawn from general peptide and lyophilized-formulation science.
• Shelf-life and in-use statements are formulation-specific. They cannot be transferred between different tesamorelin products, between strengths, or between approved and research-grade material.
• Stability has both chemical and microbiological dimensions. A solution can remain chemically intact while being unsuitable on sterility grounds, which is why in-use limits for punctured vials are typically shorter than chemical degradation alone would suggest.
• The clinical papers cited above report outcomes in defined study populations under protocol conditions; researchers did not test storage variables as an experimental factor in those trials.

Anyone with a specific question about a specific vial — including whether refrigeration applies before or after reconstitution — should consult that product's current labeling and a licensed physician or pharmacist rather than generalise from the class-level chemistry described here.

References

• Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor (Current Opinion in Investigational Drugs, 2006)
• Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009)
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs, 2011)
• Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction (AIDS, 2011)
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (The Annals of Pharmacotherapy, 2012)
• Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects (Journal of Pharmacokinetics and Pharmacodynamics, 2015)
• Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017)
• Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021)
• Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach (Scientific Reports, 2021)
• Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024)
• Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (The Journal of Infectious Diseases, 2025)
• Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol (BMJ Open, 2026)